Halyard Health (NYSE: HYH) is one of 67 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its competitors? We will compare Halyard Health to similar companies based on the strength of its risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.
Insider and Institutional Ownership
89.7% of Halyard Health shares are owned by institutional investors. Comparatively, 66.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 1.3% of Halyard Health shares are owned by insiders. Comparatively, 11.8% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent recommendations for Halyard Health and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Halyard Health Competitors||204||1142||2424||93||2.62|
Halyard Health presently has a consensus target price of $44.00, indicating a potential downside of 4.72%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.91%. Given Halyard Health’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Halyard Health has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares Halyard Health and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Halyard Health||$1.59 billion||$39.80 million||38.81|
|Halyard Health Competitors||$987.06 million||$131.70 million||229.61|
Halyard Health has higher revenue, but lower earnings than its competitors. Halyard Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Halyard Health has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Halyard Health’s competitors have a beta of 0.96, meaning that their average stock price is 4% less volatile than the S&P 500.
This table compares Halyard Health and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Halyard Health Competitors||-128.68%||-46.53%||-12.33%|
Halyard Health competitors beat Halyard Health on 7 of the 13 factors compared.
Halyard Health Company Profile
Halyard Health, Inc. is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections. The Company address healthcare needs, such as reducing the use of opioids, while helping patients move from surgery to recovery. The Medical Devices segment’s products include post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems and enteral feeding tubes. The S&IP segment includes product offerings, such as sterilization wrap, surgical drapes and gowns, facial protection, protective apparel and medical exam gloves.
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.